Skip to main content
Premium Trial:

Request an Annual Quote

New Zealand Patent Office Issues Notice of Allowance for MDRNA Application


MDRNA said this week that it has received a notice of allowance from the Intellectual Property Office of New Zealand on a patent application covering siRNAs and delivery systems with therapeutic potential.

The application, No. 553828, is entitled, "Methods of Treating an Inflammatory Disease by Double-Stranded Ribonucleic Acid," according to the company.

"Allowed claims cover small interfering RNAs directed against the tumor necrosis factor gene, as well as several of the company's key nucleic acid condensing and delivery peptide motifs in combination with a siRNA directed against TNF," MDRNA added.